He wāhanga hiko kei roto i ngā pūtau matepukupuku, nō reira ka pāngia rātou e ngā mara hiko. Ko te whakamahinga o ngā mara hiko tauutuutu (TTFields) ki ngā pukupuku totoka ka aro motuhake, ka whakararuraru hoki i te mitosis i ngā wāhanga rerekē o te wehenga o ngā pūtau matepukupuku, ka whakarei ake i te ārai mate pukupuku, ka whakaheke i te urupare kino o te DNA e arahi ana ki te matenga o ngā pūtau matepukupuku. Kua whakaatuhia e ngā whakamātautau haumanu ka whakanui ake te rongoā TTFields i ngā reiti oranga o te glioblastoma, te mesothelioma me ngā matepukupuku pūkahukahu kore-pūtau iti kua horapa, nō reira i whakaaetia ai te rongoā TTFields mō te rongoā i ēnei matepukupuku i mua ake nei. Ināianei, i te 12 o Pēpuere 2026, i runga i ngā hua o tētahi whakamātautau haumanu tata nei, kua whakaaetia e te FDA te rongoā TTFields mō te matepukupuku repe taikaha kua whanake haere i te rohe. He mea nui tēnei nā te mea he uaua te whakahaere haumanu o te matepukupuku repe taikaha i runga i te tirohanga o te matapae kino me te reiti oranga iti.
Kua whakaaetia ngā mara hiko tauutuutu, e mōhiotia ana ko ngā Mara Maimoatanga Tumor (TTFields), e tukuna ana e tētahi taputapu whakaputa mara hiko kore-whakaeke kawe hei rongoā i te mate pukupuku repeure kua horapa haere i roto i ngā pakeke.
Optune Pax, te taputapu kawe i whakawhanakehia e Ko Novocure i whakaaetia mō te rongoā i te mate pukupuku repe taikaha ā-rohe i te 12 o Pēpuere 2026 e te FDA i runga i ngā hua o te whakamātautau haumanu wāhanga 3 i whakaatu ko te tāpiri o ngā TTFields ki ngā rongoā chemotherapy paerewa tiaki gemcitabine me nab-paclitaxel (GnP) i whakapai ake i te oranga whānui mā te rua marama pea ki te whakataurite ki te GnP anake. I whiwhi te taputapu i te tohu Breakthrough Device i mua ake o Hakihea 2024.
Ko te rongoā Tumour Treating Fields (TTFields) he rongoā mate pukupuku kore-whakaeke. Ka whakamahia he mara hiko sinusoidal motuhake mai i te 100 kHz ki te 300 kHz, e whakararuraru ana i te wehenga tere o ngā pūtau mate pukupuku, ā, ka mate ngā pūtau, engari kāore e pāngia ngā pūtau hauora. He pai te manawanui o ngā tūroro ki tēnei rongoā, ā, kua kitea he pai ake te oranga whānui o ngā tūroro he pukupuku totoka.
Kua whakaaetia kētia a TTFields maimoatanga o ngā mate pukupuku pūkahukahu glioblastoma multiforme (GBM) hou kua kitea me te hoki mai anō, te mate pukupuku pleural mesothelioma malignant (MPM) me te mate pukupuku pūkahukahu kore-pūtau iti kua horapa. Ko te mate pukupuku repeure kua horapa ā-rohe te mea hou rawa atu i te rārangi.
He mate kino te mate pukupuku repeure, he kino te āhua o tōna oranga, ā, he iti te maha o ngā mate e ora ai. Ko tētahi o ngā mate pukupuku tino uaua ki te rongoā. Mā te whakaaetia o TTFields mō te mate pukupuku repeure kua horapa ki te taumata tuatoru, ka tukuna he huarahi maimoatanga hou ki ngā tūroro.
***
Tohutoro:
- Pānui a te FDA – Kua Whakaaetia e te FDA te Pūrere Tuatahi o tōna Momo hei Rongoā i te Matepukupuku Repeure. I tāngia i te 12 o Pēpuere 2026. Kei te wātea mai i https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-device-treat-pancreatic-cancer
- Babiker HM et al 2025. Ngā Marae Rongoā Puku me te Gemcitabine me te Nab-Paclitaxel mō te Adenocarcinoma Pancreatic Matatau ā-Rohe: Rangahau PANOVA-3 Wāhanga III Matapōkeretia, Tuwhera-Tapanga. J Clin Oncol 43, 2350-2360(2025) Pukapuka 43, Tau 21. DOI: https://doi.org/10.1200/JCO-25-00746
- Te Pānga o ngā Marae Maimoatanga Puku (TTFields, 150 kHz) hei Maimoatanga Raina-Mua o te Adenocarcinoma Pancreatic Matatau-ā-Rohe e Honohono Ana ki te Gemcitabine me te Nab-paclitaxel (PANOVA-3). NCT03377491. Kei te wātea mai i https://clinicaltrials.gov/study/NCT03377491?tab=study
- Serventi JN me Newton HB, 2025. Ngā Marae Maimoatanga Puku: He Rongoā Auaha mō te Glioblastoma me ētahi atu Puku Totoka. JADPRO Pukapuka 16, Nama 5 (Hepetema/Oketopa 2025). DOI: https://doi.org/10.6004/jadpro.2025.16.5.3
- Li, Xing et al 2023. He arotake i ngā mara rongoā pukupuku (TTFields): ngā whanaketanga i roto i ngā tono haumanu me ngā māramatanga tikanga. Radiology and Oncology Volume 57 (2023): Putanga 3 (Hepetema 2023), DOI: https://doi.org/10.2478/raon-2023-0044
- Shams S. me Patel CB, 2022. Ngā tikanga mahi ārai-matepukupuku o ngā mara hiko tauutuutu rongoā (ngā mara maimoatanga pukupuku [TTFields]). Journal of Molecular Cell Biology, Pukapuka 14, Putanga 8, Ākuhata 2022, mjac047. DOI: https://doi.org/10.1093/jmcb/mjac047
***
Tikanga Mahi a TTFields
 to solid tumours selectively target and disrupt mitosis at different stages in division of cancer cells, enhance antitumor immunity and downregulate DNA damage response leading to death of cancer cells. Clinical trials have shown that TTFields therapy enhances survival rates of glioblastoma, mesothelioma and metastatic non–small cell lung cancer cases hence TTFields therapy was approved for the treatment of these cancer cases earlier. Now, on 12 February 2026, based on the results from a recent clinical trial, FDA has approved TTFields therapy for locally advanced pancreatic cancer as well. This is significant given clinical management of pancreatic cancer is challenging in view of poor prognosis and low survival rate.){kind=link}